(CRBN) Corbion - Ratings and Ratios
Lactic, Acid, Derivatives, Emulsifiers, Bioplastics
Description: CRBN Corbion August 21, 2025
Corbion NV, a Dutch specialty chemicals company, operates in a sector driven by demand for sustainable and innovative solutions. The companys quarterly income tax expense is a critical component of its financial performance, influencing its net income and profitability.
To evaluate Corbion NVs stock (CRBN), its essential to consider key performance indicators (KPIs) such as revenue growth, gross margin, and return on equity (RoE). The companys RoE of 15.94% indicates a relatively strong ability to generate profits from shareholders equity. Additionally, the forward price-to-earnings (P/E) ratio of 12.89 suggests that the stock may be undervalued, as it implies a lower expected earnings multiple compared to its current P/E of 14.74.
The specialty chemicals industry is influenced by various economic drivers, including global demand for food preservation, pharmaceuticals, and bioplastics. Corbion NVs market capitalization of 962.10M EUR indicates a moderate size, potentially allowing for agile decision-making while still maintaining a significant market presence. The stocks beta of 1.015 suggests that its price movements are closely correlated with the overall market, implying a relatively average level of systematic risk.
To further analyze CRBN, its crucial to examine the companys quarterly earnings reports, focusing on metrics such as sales growth, operating expenses, and tax rates. By deconstructing these components, investors can gain a deeper understanding of Corbion NVs financial health and identify potential areas for improvement. Moreover, monitoring industry trends, competitor activity, and macroeconomic factors will help investors make informed decisions about the stocks future prospects.
CRBN Stock Overview
| Market Cap in USD | 1,186m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
CRBN Stock Ratings
| Growth Rating | -72.5% |
| Fundamental | 66.9% |
| Dividend Rating | 51.4% |
| Return 12m vs S&P 500 | -40.2% |
| Analyst Rating | - |
CRBN Dividends
| Dividend Yield 12m | 3.72% |
| Yield on Cost 5y | 1.83% |
| Annual Growth 5y | 6.11% |
| Payout Consistency | 92.3% |
| Payout Ratio | 57.1% |
CRBN Growth Ratios
| Growth Correlation 3m | 25.2% |
| Growth Correlation 12m | -86.3% |
| Growth Correlation 5y | -86.5% |
| CAGR 5y | -13.73% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.24 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.36 |
| Sharpe Ratio 12m | 0.45 |
| Alpha | -43.28 |
| Beta | 0.978 |
| Volatility | 30.69% |
| Current Volume | 127.5k |
| Average Volume 20d | 118.7k |
| Stop Loss | 16.6 (-3.5%) |
| Signal | -0.59 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (111.1m TTM) > 0 and > 6% of Revenue (6% = 132.9m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA 5.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.11% (prev 1.67%; Δ 2.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 226.3m > Net Income 111.1m (YES >=105%, WARN >=100%) |
| Net Debt (404.9m) to EBITDA (300.7m) ratio: 1.35 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (58.1m) change vs 12m ago -2.77% (target <= -2.0% for YES) |
| Gross Margin 23.54% (prev 22.70%; Δ 0.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 139.4% (prev 72.11%; Δ 67.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.47 (EBITDA TTM 300.7m / Interest Expense TTM 45.7m) >= 6 (WARN >= 3) |
Altman Z'' 3.80
| (A) 0.06 = (Total Current Assets 514.2m - Total Current Liabilities 423.3m) / Total Assets 1.45b |
| (B) 0.47 = Retained Earnings (Balance) 685.1m / Total Assets 1.45b |
| (C) 0.13 = EBIT TTM 204.2m / Avg Total Assets 1.59b |
| (D) 0.94 = Book Value of Equity 685.1m / Total Liabilities 727.3m |
| Total Rating: 3.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.86
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield -5.21% = -2.60 |
| 3. FCF Margin -3.35% = -1.25 |
| 4. Debt/Equity 0.61 = 2.32 |
| 5. Debt/Ebitda 1.35 = 1.23 |
| 6. ROIC - WACC (= 7.91)% = 9.89 |
| 7. RoE 15.36% = 1.28 |
| 8. Rev. Trend 78.33% = 5.87 |
| 9. EPS Trend -17.38% = -0.87 |
What is the price of CRBN shares?
Over the past week, the price has changed by -0.29%, over one month by +5.20%, over three months by -4.02% and over the past year by -28.59%.
Is Corbion a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CRBN is around 13.83 EUR . This means that CRBN is currently overvalued and has a potential downside of -19.59%.
Is CRBN a buy, sell or hold?
What are the forecasts/targets for the CRBN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.6 | 31.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 15.4 | -10.6% |
CRBN Fundamental Data Overview January 01, 1970
Market Cap EUR = 1.02b (1.02b EUR * 1.0 EUR.EUR)
P/E Trailing = 15.7838
P/E Forward = 15.1057
P/S = 0.7855
P/B = 1.3296
Beta = 0.978
Revenue TTM = 2.21b EUR
EBIT TTM = 204.2m EUR
EBITDA TTM = 300.7m EUR
Long Term Debt = 244.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 200.2m EUR (from shortLongTermDebt, last quarter)
Debt = 445.0m EUR (Calculated: Short Term 200.2m + Long Term 244.8m)
Net Debt = 404.9m EUR (from netDebt column, last quarter)
Enterprise Value = 1.42b EUR (1.02b + Debt 445.0m - CCE 40.1m)
Interest Coverage Ratio = 4.47 (Ebit TTM 204.2m / Interest Expense TTM 45.7m)
FCF Yield = -5.21% (FCF TTM -74.1m / Enterprise Value 1.42b)
FCF Margin = -3.35% (FCF TTM -74.1m / Revenue TTM 2.21b)
Net Margin = 5.02% (Net Income TTM 111.1m / Revenue TTM 2.21b)
Gross Margin = 23.54% ((Revenue TTM 2.21b - Cost of Revenue TTM 1.69b) / Revenue TTM)
Gross Margin QoQ = 25.56% (prev 23.35%)
Tobins Q-Ratio = 0.98 (Enterprise Value 1.42b / Total Assets 1.45b)
Interest Expense / Debt = 4.92% (Interest Expense 21.9m / Debt 445.0m)
Taxrate = 2.64% (1.20m / 45.4m)
NOPAT = 198.9m (EBIT 204.2m * (1 - 2.64%))
Current Ratio = 1.21 (Total Current Assets 514.2m / Total Current Liabilities 423.3m)
Debt / Equity = 0.61 (Debt 445.0m / totalStockholderEquity, last quarter 726.2m)
Debt / EBITDA = 1.35 (Net Debt 404.9m / EBITDA 300.7m)
Debt / FCF = -5.46 (negative FCF - burning cash) (Net Debt 404.9m / FCF TTM -74.1m)
Total Stockholder Equity = 723.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.64% (Net Income 111.1m / Total Assets 1.45b)
RoE = 15.36% (Net Income TTM 111.1m / Total Stockholder Equity 723.2m)
RoCE = 21.10% (EBIT 204.2m / Capital Employed (Equity 723.2m + L.T.Debt 244.8m))
RoIC = 16.06% (NOPAT 198.9m / Invested Capital 1.24b)
WACC = 8.15% (E(1.02b)/V(1.46b) * Re(9.62%) + D(445.0m)/V(1.46b) * Rd(4.92%) * (1-Tc(0.03)))
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.80%
Fair Price DCF = unknown (Cash Flow -74.1m)
EPS Correlation: -17.38 | EPS CAGR: -58.19% | SUE: 0.0 | # QB: 0
Revenue Correlation: 78.33 | Revenue CAGR: 74.02% | SUE: -0.06 | # QB: 0